Coverage Churn Is Now a Balance-Sheet Variable
Analysis · Pinnacle Services Corporation · September 2026
Five insurers are stepping back from Medicare Advantage, by Becker's count in mid-August: Providence Health Plan winding down after a rescue deal with a national carrier collapsed; Humana leaving plans that cover 600,000 members in 2027; Clear Spring Health gone since June 1; Molina dropping its Medicare Advantage drug plans; Presbyterian Health Plan discontinuing most of its offerings, about 30,000 members. JAMA researchers found that 10% of Medicare Advantage enrollees had already been forced to switch plans entering 2026, before any of those exits take effect.
Medicaid is churning at larger scale. Epic Research's analysis of more than 550 million encounters, published September 1, found that 7.6% of emergency visits are now paid in cash, up from 5.5% in early 2022, while Medicaid's share of emergency encounters fell from 18.2% to 16.1%. Behind those lines sit the 25 million people who lost Medicaid in the post-pandemic unwinding and the roughly six million more the Congressional Budget Office projects will lose it over the next decade under last year's reconciliation law.
Exits and disenrollments read as insurance news. Operationally they are eligibility events, and laboratory claims hit the mismatch first.
Why the laboratory is last to know
A laboratory bills downstream of an encounter it did not conduct, for a patient who was never in its building, against coverage information that was captured by someone else at a moment that may already be stale. When a plan winds down, when a member is moved to a new carrier at open enrollment, or when a Medicaid redetermination lapses, the requisition still arrives, the specimen is still processed, and the claim goes to the payer of record. The answer comes back weeks later as a denial naming the wrong payer, a terminated eligibility, a capitated arrangement, or a coordination-of-benefits problem. Coverage rarely fails at the front desk. It fails silently, between the order and the remit.
Those failures have codes, and the codes are where the money is measured. In the composite twelve-month book of Recovr's laboratory customers, stated at expected payer fees, claims denied as not covered by the payer billed — CARC 109 — came to $6.0 million, and claims denied because the patient sat in a capitated managed-care arrangement — CARC 24 — to $5.4 million. Neither is a question of medical necessity or documentation. Both are questions of who was actually on risk for the patient on the date of service.
Churn as a recovery category, not a write-off
The distinction that matters is what recovers the money once the denial has posted. On the twelve-month book of a national collection of more than 12,000 physicians, wrong-payer and misrouted claims — CARC 109 and B11 — carried $1.40 million in denied charges on 14,599 claims, of which Recovr's models identified $1.31 million as recoverable, 8.9% of everything recoverable in the book, at a modeled 89.7% success rate. The action is not an appeal. It is coverage discovery followed by a reroute: find the payer that was on risk, and file a new claim with that payer before its filing limit runs. In the platform's live decision log, reroutes were 39% of all frequency-code decisions in the first two weeks of September.
Coordination-of-benefits denials — CARC 22 — behave the same way and move with the churn. On the same book they rose from $31,950 on 596 claims in June to $54,100 on 753 claims in August, 61% of it identified as recoverable, spread across Optum, Medicare, Medicaid and a regional plan, and concentrated in surgical pathology codes 88305, 88341, 88342, 88304 and 88307. A secondary claim to the correct payer recovers it. A letter does not.
What does not recover is the eligibility bucket itself: CARC 31, patient cannot be identified as our insured, and its relatives carried $656,000 in denied charges on 9,933 claims, of which $3,700 was recoverable. When the patient was not covered by anyone on the date of service, the post-adjudication answer is a patient statement or a write-off, and no amount of automation changes that. The value of a machine-checkable coverage interrogation is precisely in sorting the two populations — the misrouted claim that has a payer somewhere, and the uncovered patient who does not — before staff time is spent on either.
The calendar makes it worse
Churn and the filing clock compound. A claim that went to the wrong payer in June is not merely denied; it is denied while the correct payer's filing window keeps running. In the same physician book, 77,500 recoverable denials worth $8.6 million passed their filing deadlines unrecovered over the trailing twelve months, scored at 52% average odds of success and $4.4 million in expected recovery. The 2027 Medicare Advantage exits land in January; the reshuffle they trigger starts with open enrollment in October, and the Medicaid redeterminations run continuously. Every reshuffle rewrites enrollment files, and every rewrite produces a cohort of misrouted claims with a deadline attached.
Coverage volatility is no longer an occasional patient-access problem that billing inherits. It is a permanent operating condition, one that manual follow-up cannot keep pace with and automated coverage discovery, reroute and secondary-claim pipelines are built for. Eligibility used to be a front-desk question. It is now a balance-sheet variable, and the line it moves is the one labeled misrouted.
Sources: Becker's Payer Issues, "5 insurers stepping back from Medicare Advantage," August 17, 2026, citing JAMA on plan switching; Healthcare Dive, "Medicaid losses leave more patients paying cash, Epic finds," September 1, 2026, on Epic Research's encounter analysis, with KFF and CBO context. Laboratory composite figures are from Recovr's July 2026 case study, stated at expected payer fees; physician-book figures are from Recovr's denial analytics for a national collection of more than 12,000 physicians and are model-identified, not realized recoveries.
